Document is current
Any future updates will be listed below
-
Authors
Mourisse, Louis https://orcid.org/0000-0001-5785-9172
Ostermann, Marlies
Thiessen, Steven
Dumoulin, Alexander
Vlaar, Alexander P. J.
Hoste, Eric
Mosbahi, Selim
Schneider, Antoine
Zarbock, Alexander
Boehm, Johannes
Rosenberger, Peter
Thielmann, Matthias
Dubois, Eric
Powell-Tuck, Jonah
Baig, Kamran
Renette, Wencke
Meex, Ingrid
Klop-Rhiel, Margreet
Opschoor, Krijna
Vandenberghe, Wim
Siepe, Matthias
Strauss, Christian
Wirth, Felix
Winkel, Matthias
Hof, Liesbeth
Kraan, Maarten
Bernholz, Juliane
Pickkers, Peter
,
Geelink, Nienke
Vermeiren, Daisy
Van Hecke, Jolien
De Smeytere, Anouska
Decoster, Lesley
Schützenmeister, Katrin
Booke, Hendrik
Mertes, Moritz
Bernard, Alice
Mirakaj, Valbona
Hermann, Sabine
Thielmann, Matthias
Ristau, Wolfgang
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct06168799 at ClinicalTrials.govDocuments that mention this clinical trial
A multicenter randomized, double-blinded placebo-controlled phase 2 trial to evaluate safety and efficacy of ilofotase alfa in patients at risk for kidney injury following open heart surgery
https://doi.org/10.1007/s00134-026-08596-y
-
Funding
Funding for this research was provided by:
AM-Pharma BV
- License Information
-
More Information
Article History
Received: 28 May 2026
Accepted: 11 August 2026
First Online: 21 September 2026
Declarations
Conflicts of interest: LM: LM serves as the Medical and Scientific Advisor for this trial. The Intensive Care Research Department at Radboud UMC Nijmegen, the Netherlands, is reimbursed for this role, while LM does not receive any direct financial compensation. MO: MO received research funding from Baxter and Biomerieux which was paid to the institution. ST: no conflict of interest to declare. AD: no conflict of interest to declare. AV: Received consulting fees and grants from Edwards Lifesciences, AM-Pharma and CSL Behring paid to the institution. EH: no conflict of interest to declare. SM: no conflict of interest to declare. AS: no conflict of interest to declare. AZ: AZ has received consulting fees from Astute-Biomerieux, Baxter, Bayer, Novartis, Guard Therapeutics, Dropshot Therapeutics, Chugai, Viatris, AM-Pharma, Paion, Fresenius, research funding from Astute-Biomerieux, Fresenius, Baxter, and speakers’ fees from Astute-Biomerieux, Fresenius, Baxter, JoB: no conflict of interest to declare. PR: no conflict of interest to declare. MT: no conflict of interest to declare. ED: no conflict of interest to declare. JPK: no conflict of interest to declare. KB: no conflict of interest to declare. WR: no conflict of interest to declare. IM: no conflict of interest to declare. MKR: no conflict of interest to declare. KO: no conflict of interest to declare. WV: no conflict of interest to declare. MS: no conflict of interest to declare. CS: no conflict of interest to declare. FW: no conflict of interest to declare. MW: is an employee of AM-Pharma bv. LH: is an employee of AM-Pharma bv. MK: is an employee of AM-Pharma bv. JB: is an employee of AM-Pharma bv. PP: PP received travel and consultancy reimbursements from AM-Pharma. AM-Pharma funded the trial and supplied resources for the conduction of the trial.
